Literature DB >> 20869848

Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS).

Courtney Forbes1, Jack J Blanchard, Melanie Bennett, William P Horan, Ann Kring, Raquel Gur.   

Abstract

As part of an ongoing scale development process, this study provides an initial examination of the psychometric properties and validity of a new interview-based negative symptom instrument, the Clinical Assessment Interview for Negative Symptoms (CAINS), in outpatients with schizophrenia or schizoaffective disorder (N = 37). The scale was designed to address limitations of existing measures and to comprehensively assess five consensus-based negative symptoms: asociality, avolition, anhedonia (consummatory and anticipatory), affective flattening, and alogia. Results indicated satisfactory internal consistency reliability for the total CAINS scale score and promising inter-rater agreement, with clear areas identified in need of improvement. Convergent validity was evident in general agreement between the CAINS and alternative negative symptom measures. Further, CAINS subscales significantly correlated with relevant self-report emotional experience measures as well as with social functioning. Discriminant validity of the CAINS was strongly supported by its small, non-significant relations with positive symptoms, general psychiatric symptoms, and depression. These preliminary data on an early beta-version of the CAINS provide initial support for this new assessment approach to negative symptoms and suggest directions for further scale development.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20869848      PMCID: PMC2981616          DOI: 10.1016/j.schres.2010.08.039

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  19 in total

Review 1.  ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004.

Authors:  S A Montgomery; B van Zwieten-Boot
Journal:  Eur Neuropsychopharmacol       Date:  2006-07-13       Impact factor: 4.600

2.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

3.  A meta-analysis of controlled research on social skills training for schizophrenia.

Authors:  Matthew M Kurtz; Kim T Mueser
Journal:  J Consult Clin Psychol       Date:  2008-06

4.  Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia.

Authors:  Jack J Blanchard; Ann M Kring; William P Horan; Raquel Gur
Journal:  Schizophr Bull       Date:  2010-09-22       Impact factor: 9.306

Review 5.  Anhedonia in schizophrenia: a review of assessment strategies.

Authors:  William P Horan; Ann M Kring; Jack J Blanchard
Journal:  Schizophr Bull       Date:  2005-10-12       Impact factor: 9.306

Review 6.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Authors:  Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2004-09-01       Impact factor: 13.382

7.  Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure.

Authors:  David E Gard; Ann M Kring; Marja Germans Gard; William P Horan; Michael F Green
Journal:  Schizophr Res       Date:  2007-05-09       Impact factor: 4.939

8.  A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale.

Authors:  D Addington; J Addington; M Atkinson
Journal:  Schizophr Res       Date:  1996-05       Impact factor: 4.939

Review 9.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Authors:  S Leucht; D Arbter; R R Engel; W Kissling; J M Davis
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

10.  Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor.

Authors:  Til Wykes; Craig Steel; Brian Everitt; Nicholas Tarrier
Journal:  Schizophr Bull       Date:  2007-10-25       Impact factor: 9.306

View more
  34 in total

Review 1.  Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.

Authors:  Kazuto Oya; Yuki Matsuda; Shinji Matsunaga; Taro Kishi; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-25       Impact factor: 5.270

2.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

3.  A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.

Authors:  Dawn I Velligan; David Roberts; Jim Mintz; Natalie Maples; Xueying Li; Elisa Medellin; Matt Brown
Journal:  Schizophr Res       Date:  2015-05-01       Impact factor: 4.939

4.  Nonverbal social communication and gesture control in schizophrenia.

Authors:  Sebastian Walther; Katharina Stegmayer; Jeanne Sulzbacher; Tim Vanbellingen; René Müri; Werner Strik; Stephan Bohlhalter
Journal:  Schizophr Bull       Date:  2015-02-01       Impact factor: 9.306

5.  Methodological issues in negative symptom trials.

Authors:  Stephen R Marder; David G Daniel; Larry Alphs; A George Awad; Richard S E Keefe
Journal:  Schizophr Bull       Date:  2011-01-26       Impact factor: 9.306

Review 6.  Psychometric evaluation of the negative syndrome of schizophrenia.

Authors:  Maria Paz Garcia-Portilla; Leticia Garcia-Alvarez; Pilar A Saiz; Susana Al-Halabi; Maria Teresa Bobes-Bascaran; Maria Teresa Bascaran; José Muñiz; Julio Bobes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 5.270

7.  Screening for negative symptoms: preliminary results from the self-report version of the Clinical Assessment Interview for Negative Symptoms.

Authors:  Stephanie G Park; Katiah Llerena; Julie M McCarthy; Shannon M Couture; Melanie E Bennett; Jack J Blanchard
Journal:  Schizophr Res       Date:  2012-01-21       Impact factor: 4.939

8.  From perception to functional outcome in schizophrenia: modeling the role of ability and motivation.

Authors:  Michael F Green; Gerhard Hellemann; William P Horan; Junghee Lee; Jonathan K Wynn
Journal:  Arch Gen Psychiatry       Date:  2012-12

9.  Sleep dysfunction and thalamic abnormalities in adolescents at ultra high-risk for psychosis.

Authors:  Jessica R Lunsford-Avery; Joseph M Orr; Tina Gupta; Andrea Pelletier-Baldelli; Derek J Dean; Ashley K Smith Watts; Jessica Bernard; Zachary B Millman; Vijay A Mittal
Journal:  Schizophr Res       Date:  2013-10-04       Impact factor: 4.939

10.  Physical activity level and medial temporal health in youth at ultra high-risk for psychosis.

Authors:  Vijay A Mittal; Tina Gupta; Joseph M Orr; Andrea Pelletier-Baldelli; Derek J Dean; Jessica R Lunsford-Avery; Ashley K Smith; Briana L Robustelli; Daniel R Leopold; Zachary B Millman
Journal:  J Abnorm Psychol       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.